Unleash the potential
ECIO | April 28th – May 1st | Palma de Mallorca - Spain
At the dawn of a new era in unresectable HCC: all you need to know
Sunday, April 28th · 14:00–14:45 CET (45min) · Auditorium 2
Prof. Lorenza Rimassa
Medical Oncology and Hematology Unit Humanitas Cancer Center
Humanitas University and IRCCS Humanitas Research Hospital (Milan, IT)
Prof. Maria Reig.
Head of Liver Oncology Unit (BCLC)
BCLC group. Liver Unit.Hospital Clinic.
Barcelona (Barcelona, SP)
Add to your calendar
Inflammatory signatures of different types of chemoembolizations paving the way for future combination treatment in HCC
Dr Rony Avritscher MD Anderson Cancer Center, Houston (Texas, USA)
How I practice cTACE to improve HCC patients’ outcomes

Prof. Cristina Mosconi Policlinico S.Orsola-Malpighi, (Bologna, IT)
Unresectable HCC management: today practices and future evolution

Dr Maria Reig BCLC group. Liver Unit. Hospital Clinic. Barcelona (Barcelona, SP)
This symposium will be followed by a Q&A session
with Dr Rony Avritscher at 16:00 CET at Booth #04
Hepatic lymphatics and lymphorrhea - imaging and interventional management (15min)
Come and meet the expert with all your questions or just your interest in Lymphangiography.
Monday afternoon and Tuesday morning .
Prof. Claus Pieper– University Hospital Bonn (GER)
Book your timeslots
Curious to understand better how cTACE combined with immuno-therapies
could change the treatment paradigm in HCC1 (BCLC B)?
Join the interactive discussion at our booth #04
1- EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterialchemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Journal of Clinical Oncology (
Lipiodol® Ultra Fluid (Ethyl esters of iodized fatty acids of poppy seed oil) no está registrado en España.
Lipiodol® Ultra Fluid (Ethyl esters of iodized fatty acids of poppy seed oil) is not registered in Spain.
For current and complete prescribing information refer to the local Summary of Product Characteristics (SmPC) and /or contact your local Guerbet organization. This information is intended for an international audience or is provided during an international event. Be aware that Indications, posology, and presentations may differ from country to country.
© Guerbet Group 2024
Legal mentions & SmPC
P24002757 – March 2024